Most Market Roundup June 16th,2017 BLACK FOX EQUITY Market Sensex 31056.40 (-0.06) Nifty 9588.05 (+0.10) Closing Bell: The benchmark Sensex cut down its early gains on Friday and the Nifty moved in a range after healthcare and IT counters came under selling pressure. The Sensex resumed higher at 31,160.47 and firmed up to a high of 31,182.73 in view of higher global cues. However, it read 31,103.30 at 12.13pm, a gain of 27.57 points, or 0.09%. The NSE 50- share Nifty moved up marginally by 6.40 points, or 0.07%, to 9,584.45. The big gainers were ITC 1.66%, along with Tata Motors, M&M, GAIL and Coal India. However, Lupin fell by 3.75%. Dr Reddy’s Lab, Wipro, Cipla and Sun Pharma, too, retreated. Overseas, most Asian stocks were trading higher. US stocks fell for the fourth time in five days as selling in technology shares resumed. Meanwhile, foreign funds sold shares net Rs645.35 crore on Thursday, as per the provisional figures. Oil equipment companies were trading higher. GOL Offshore Ltd rose 20%, Aban Offshore Ltd rose 7.4%, Dolphin Offshore Enterprises India Ltd rose 13%, Oil Country Tubular Ltd rose 18%. Tata Motors Ltd rose 1.5% to Rs 455. Tata Motors Ltd and two other group entities will sell a 43% stake in Tata Technologies Ltd to an affiliate of US-based private equity firm Warburg Pincus Llc for $360 million (Rs2,231 crore), seeking to raise funds to reduce debt. Ipca Laboratories Ltd fell 15% to Rs437 after the company said in a notice to BSE that it received communications from US drug regulator (USFDA) stating that all the drugs manufactured from its units situated at SEZ Indore and Piparia manufacturing facilities will be refused admission in the US until it demonstrates that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with CGMP. With inflation still distant from its target, the Bank of Japan maintained its promise to keep pouring stimulus into the economy, days after the Federal Reserve raised interest rates and set out more details of its plan to normalize policy. The BOJ will continue to manage the yield curve through a negative interest rate and buying trillions of yen worth of bonds, it said in a statement Friday. The result was expected by all 43 economists surveyed by Bloomberg. Crude held losses near a seven-month low, gold slid more than 1.5 percent and base metals continue falter. However, softening commodity prices did little bolster arguments that inflation will pick up the pace, even as the U.S. labour market remains on strong footing – raising the spectre that central officials made a policy error. The initial public offer (IPO) of Eris Lifesciences got subscribed 2 per cent on the first day of the offer. The public offer received bids for 2,72,352 shares against the total issue size of 1,59,48,750 shares, data available with the NSE till 11.30 am showed. Shares of India’s first listed pureplay gaming company, Delta Corp, have surged nearly 180 per cent in last 16 months to Rs 161.25 as of June 16, 2017 from Rs 57.70 in February 2016. US stocks weakened overnight, as the Nasdaq led losses on Wall Street with a 0.5 per cent drop, dragged lower by shares including Apple and Alphabet, which tumbled on bearish analysts' reports. The S&P500 technology index also declined 0.5 per cent. The broader S&P500 index fell 0.2 per cent and the Dow Jones Industrial Average slipped 0.1 per Exchange Toady Pre. Day BSE (CASH) NA 3410 BSE(Derivative) 36.22 41.04 NSE (Cash) 27153 23933 NSE(Derivative) 286132 844730 Exchange Today Pev. Day Total 300348 899497 Group NIFTY IND BSE INDEX Advance 25 88 Decline 26 113 Unchanged 00 0 Symbol LTP % TATAMTRDVR 281.85 +3.20 KOTAKBANK 984.45 +2.27 ACC 1643.00 +1.92 ULTRACEMCO 4110.70 +1.65 TATAMOTORS 455.35 +1.57 Symbol LTP % Change LUPIN 1130.60 -4.38 SUNPHARMA 529.10 -2.74 CIPLA 535.05 -2.62 WIPRO 254.60 -2.40 IBULHSGFIN 1129.05 -1.74 Exchange No. of Contract s Tu rn Ov Index Futures 129914 10277 Stock Futures 592077 42176 Index Options 2509867 204276 Stock Options 409305 29403 F&O Total 3641163 286132 CASH VOLUME (Rs In Cr.) ADVANCED / DECLINE TOP INDEX GAINERS TOP INDEX LOSERS DERIVATIVE VOL 417. Stock future Price Rs. Qty Value Contract RELIANCE 1387.1 24471 30252 AUROPHARMA 653.0 20874 21907 LUPIN 1130.6 14073 21909 INFY 937.0 12311 72010 ACTIVE STOCK IN FUTURE
Closing Bell: The benchmark Sensex cut down its early gains on Friday and the Nifty moved in a range after healthcare and IT counters came under selling pressure. The Sensex resumed higher at 31,160.47 and firmed up to a high of 31,182.73 in view of higher global cues. However, it read 31,103.30 at 12.13pm, a gain of 27.57 points, or 0.09%. The NSE 50-share Nifty moved up marginally by 6.40 points, or 0.07%, to 9,584.45. The big gainers were ITC 1.66%, along with Tata Motors, M&M, GAIL and Coal India. However, Lupin fell by 3.75%. Dr Reddy’s Lab, Wipro, Cipla and Sun Pharma, too, retreated. Overseas, most Asian stocks were trading higher. US stocks fell for the fourth time in five days as selling in technology shares resumed. Meanwhile, foreign funds sold shares net Rs645.35 crore on Thursday, as per the provisional figures. Oil equipment companies were trading higher. GOL Offshore Ltd rose 20%, Aban Offshore Ltd rose 7.4%, Dolphin Offshore Enterprises India Ltd rose 13%, Oil Country Tubular Ltd rose 18%. Tata Motors Ltd rose 1.5% to Rs 455. Tata Motors Ltd and two other group entities will sell a 43% stake in Tata Technologies Ltd to an affiliate of US-based private equity firm Warburg Pincus Llc for $360 million (Rs2,231 crore), seeking to raise funds to reduce debt. Ipca Laboratories Ltd fell 15% to Rs437 after the company said in a notice to BSE that it received communications from US drug regulator (USFDA) stating that all the drugs manufactured from its units situated at SEZ Indore and Piparia manufacturing facilities will be refused admission in the US until it demonstrates that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with CGMP. With inflation still distant from its target, the Bank of Japan maintained its promise to keep pouring stimulus into the economy, days after the Federal Reserve raised interest rates and set out more details of its plan to normalize policy. The BOJ will continue to manage the yield curve through a negative interest rate and buying trillions of yen worth of bonds, it said in a statement Friday. The result was expected by all 43 economists surveyed by Bloomberg. Crude held losses near a seven-month low, gold slid more than 1.5 percent and base metals continue falter. However, softening commodity prices did little bolster arguments that inflation will pick up the pace, even as the U.S. labour market remains on strong footing – raising the spectre that central officials made a policy error. The initial public offer (IPO) of Eris Lifesciences got subscribed 2 per cent on the first day of the offer. The public offer received bids for 2,72,352 shares against the total issue size of 1,59,48,750 shares, data available with the NSE till 11.30 am showed. Shares of India’s first listed pureplay gaming company, Delta Corp, have surged nearly 180 per cent in last 16 months to Rs 161.25 as of June 16, 2017 from Rs 57.70 in February 2016. US stocks weakened overnight, as the Nasdaq led losses on Wall Street with a 0.5 per cent drop, dragged lower by shares including Apple and Alphabet, which tumbled on bearish analysts' reports. The S&P500 technology index also declined 0.5 per cent. The broader S&P500 index fell 0.2 per cent and the Dow Jones Industrial Average slipped 0.1 per
Exchange Toady Pre. Day BSE (CASH) NA 3410
BSE(Derivative) 36.22 41.04
NSE (Cash) 27153 23933
NSE(Derivative) 286132 844730
Exchange Today Pev. Day
BSE (Cash) 3480 3740
BSE(Derivative) 0.23 1.03
NSE (Cash) 24585 30617
NSE(Derivative) 272282 865138
Total 300348 899497
Group NIFTY IND BSE INDEX
Advance 25 88
Decline 26 113
Unchanged 00 0
Symbol LTP % Change TATAMTRDVR 281.85 +3.20
KOTAKBANK 984.45 +2.27
ACC 1643.00 +1.92
ULTRACEMCO 4110.70 +1.65
TATAMOTORS 455.35 +1.57
Symbol LTP % Change LUPIN 1130.60 -4.38
SUNPHARMA 529.10 -2.74
CIPLA 535.05 -2.62
WIPRO 254.60 -2.40
IBULHSGFIN 1129.05 -1.74
Exchange No. of Contracts
Turn Over Index Futures 129914 10277
Stock Futures 592077 42176 Index Options 2509867 204276
Stock Options 409305 29403 F&O Total 3641163 286132
The stock jumped over 11.5% intraday, the most since March 30 It has managed to add around 30 percent to its market value helped by the fourth straight day gain Trading volume is at over 5 times the 20-day average The auto component maker has a market cap of Rs 2,570 crore and has returned 130% so far this year
IPO Watch - Eris Lifesciences IPO offer to start; to allot 1.29 crore shares to anchor investors Tejas Networks IPO offer to end June 16 VLCC Health Care plans IPO this fiscal year
Things to know before Eris Lifesciences IPO –
Eris Lifesciences is an Ahmedabad-based pharma company which was incorporated in January, 2007.
The company develops, manufactures and commercialises branded pharmaceutical products for chronic lifestyle disorders with a complete focus on domestic market.
It owns and operates a manufacturing facility in Guwahati, Assam and also outsources the manufacturing of certain products to 20 third party manufacturers.
FINANCIALS:
Eris is a debt free company and has been investing its cash flows in the liquid investments. It posted 16.5% revenue and 43% PAT CAGR over FY13-17.
The EBITDA margins increased from 19.4% in FY2014 to 37.1% in FY2017. In the last two years, RoE has been healthy at 44% as against its MNC peers having RoE of 10%- 18%.
The pharma major purchased 75.5% stake in a musculoskeletal disorder focused pharma company Kinedex for Rs 77.2crore.
The company's top 10 brands have leading market share positions, while 10 mother brands represent 72.5% of its revenues.
IPO DETAILS:
Price Band: Rs 600-603 per equity share
Promoters holding Pre-Issue: 59.2%
Promoters holding Post-Issue: 55.93%
STRENGTHS:
Eris has a strong track record of growth at a CAGR of 21.7% over FY2013-17.
Company's acquisitions in specialty therapeutic segments are aiding an inorganic growth route due to opportunities in specialty therapies and a cash rich balance sheet.
Company's acquisitions in specialty therapeutic segments are aiding an inorganic growth route due to opportunities in specialty therapies and a cash rich balance sheet.
Ranked 32nd, the pharma major is one of the fastest growing pharma companies in Indian Pharmaceutical Market (IPM) and has gained 0.7% market share.
Approves fund raising plans for FY18 including raising up to Rs 3,500 crore via share sale options
Hindustan Petroleum: Expands Bathinda refinery to restart by month-end
IPCA Labs: U.S. FDA to deny admission to drugs made at three plants
NTPC: Fitch affirms NTPC at ’BBB-’; outlook stable
Sheela Foam: To be included in NSE Nifty 500; IIFL Holdings to be excluded
Tata Motors: Warburg Pincus to Buy Unit Tata Technologies Stake for $360 million
Reddy’s: Gets EIR from U.S. FDA for Miryalaguda API plant
MCX: SEBI issues framework for option trading in commodity market
Gati: Holds board meeting to approves conversion of overseas bond
Greaves Cotton: To partner Pinnacle Engines for 3-wheelers
Indian Oil, Bharat Petroleum, Hindustan Petroleum: To sign JV pact for West Coast project
Infosys: Warns of shareholder activism risk in filing, Times of India reports
JSW Steel: Crude steel output in May +1 percent YoY to 1.36
million tonne Lux Industries: Reliance Mutual Fund bought 444,103 shares
yesterday, BSE says NTPC: Azure commissions 100 mw NTPC solar project in
Andhra Pradesh Shriram Transport: Raises Rs 965 crore via debenture issue Wipro: Invests in Drivestream; to hold 26 percent stake in
company Auto: To consider issue of shares on preference basis at board
meeting on June 10
Talking Points
India invites Reliance, BP to invest in local fuel retailing BP, Reliance to revive investments in India after eight years India said to plan gold policy overhaul for $19 billion sector Uber accused of ‘rape denialism’ by victim of India assault European Steel Industry sounds alarm over U.S. trade Inquiry India Jan.-March current account deficit $3.4 billion; Estimate
$6.3 billion gap India’s May exports rise 8.3 percent YoY to $24 billion Gazprom mulls supplies to India via swaps in China, Iran India telecom regulator open to considering proposals on
interconnection usage charges India government ready to review notification on cattle trade,
says Prasad India approves raising limestone mining limits in Maharashtra India said to sell Rs 16,708 crore of FII debt quota, less than
plan Amazon, BigBasket said to be in 60-day exclusivity pact Mobikwik’s Taku confirms talks to raise $100m-$150m Indian Tycoon Mallya says ‘keep dreaming’ when it comes to
fraud RBI identifies large stressed accounts to be referred under
insolvency and bankruptcy rules 12 accounts totalling about 25 percent of Indian banking
system’s current gross bad loans qualify for resolution under new rules
India emphasizes national sales tax to roll out on July 1 India had 1.2 billion telephone subscribers as of April 30, TRAI
says Jio added 3.9 million, Bharti Airtel 2.85 million subscribers in
April Girish Wagh to head Tata Motors’ commercial vehicles business Nomura sees election math raising risks on Indian farm loans Widespread rain seen in India’s cane, tea, coffee areas SEBI releases product design for options on commodity futures RBI allows Infomerics Valuation to risk weight banks’ capital
adequacy claims India’s cabinet to meet today morning
COSMOFILMS - Cosmo Films Limited has informed the Exchange that Mr. Ambrish Jaipuria, a member of the promoter group, has at his request been granted pre clearance under Code of Internal Procedures & Conduct for prevention of Insider Trading of Cosmo Films Limited framed in pursuance of SEBI (Prohibition of Insider Trading Regulations), 2015 for sale of 1,00,000 no. of Equity Shares of the Company via Open Market. Mr. Ambrish Jaipuria has informed that he would use the funds raised from the sale of such shares for his new business/venture. Further Mr. Ambrish Jaipuria has informed that he doesn t intend to sell any further shares in the Company during the next 12 Months. TRIGYN – Trigyn Technologies Limited has informed the Exchange regarding a press release dated Jun 15, 2017, titled "Extension of UN Contract". OIL - Oil India Limited has informed the Exchange regarding Post Buyback public announcement for the attention of equity shareholders/beneficial owners of equity shares of the company. NOTICE AND CIRCULAR :
Notice No Subject Segment Name
Category Name Department PDF
20170616-13 Graded Surveillance Measure (GSM) – Shortlisting of scrips
Equity Trading DOSS
20170616-12 Settlement Schedule Offer to Buy – Acquisition Window (Takeover) for PIONEER AGRO EXTRACTS LIMITED.
General Settlement/RMS Post Trade
20170616-11 Settlement Schedule Offer to Buy – Acquisition Window (Takeover) for GOLDEN GOENKA FINCORP LIMITED
General Settlement/RMS Post Trade
20170616-10 Suspension of trading in the Units of Mutual Fund Scheme of ICICI Prudential Mutual Fund.
Mutual Fund
Corporate Actions
Listing Operations
20170616-9 Redemption of Debentures of Shriram City Union Finance Limited.
Debt Corporate Actions
Listing Operations
20170616-8 Demat Auction - 052 General Settlement/RMS Post Trade
20170616-7 Surrender of Trading Member General Others Membership Compliance
20170616-6 Change in Name General Others Membership Compliance
20170616-5 Commencement of business by Trading Member (Deposit Based Member)
General Others Membership Compliance
20170616-4 Extension of NFO of ICICI Prudential Mutual Fund on BSE StAR MF Platform
Mutual Fund
Trading Trading Operations
20170616-3 Redemption of Non-Convertible Debentures of Kotak Mahindra Prime Ltd.
Debt Corporate Actions
Listing Operations
20170616-2 Maturity/Rollover of Mutual Fund Plans of HDFC Mutual Fund.
Mutual Fund
Corporate Actions
Listing Operations
20170616-1 Launch of New Fund Offer of ICICI Prudential Mutual Fund on BSE StAR MF Platform
This document has been prepared by Black Fox Financial Pvt Ltd...... to provide information about the company(ies) and/sector(s), if any, covered in
the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not
construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Black Fox Financial Pvt Ltd is not soliciting any action based upon it. This report is not for public distribution and has
been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This
report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of
individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them
may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns
are not guaranteed and a loss of original capital may occur. Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as
opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis.
This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.
Most and it’s associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or
merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
Most and it’s associates have not received any compensation or other benefits from the subject company or
third party in connection with the research report. Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report
its affiliates and/or employees may have interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the
date of publication of the research in the securities mentioned in this report.
There are no material disciplinary action that been taken by any regulatory authority impacting equity
research analysis activities
Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no
part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views
expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and
firm revenues
Disclosure of Interest Statement Analyst ownership of the stock No Served as an officer, director or employee No
